Pharma Deals Review, Vol 2009, No 12 (2009)

Font Size:  Small  Medium  Large

Clavis and Clovis Collaborate on Anticancer Drug CP-4126

Taskin Ahmed

Abstract


Norway’s Clavis Pharma and US-based Clovis Oncology Inc are to collaborate on a US$380 M licensing partnership to develop, commercialize CP-4126, an anticancer agent.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.